We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
We recently published a list of 10 Best Small-Cap Stocks to Buy Before They Explode. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against other best small-cap stocks to buy before they explode.
Is Market Volatility Good For Small-Cap Stocks?
Since the announcement of tariffs, investors have been concerned regarding the market volatility. On February 4, 2025, Chris Clark, CEO and Co-CIO of Royce Investment Partners shared his insights as to how this market volatility can be helpful for small-cap stocks. February 2025 saw markets react negatively to President Trump’s announcement of tariffs on imports from China, Canada, and Mexico. Clark emphasized that it is still too early to gauge the positive or negative impacts of these tariffs on earnings and business fundamentals due to the current uncertainty. For instance, while initial announcements caused market disruption, subsequent negotiations led to temporary pauses on tariffs for goods from Mexico and Canada, restoring some measure of calm.
Clark highlighted that tariffs targeting Canada and Mexico appear to address non-economic issues like immigration and drug trade rather than purely economic concerns. This suggests they may be short-lived if their objectives are achieved. However, if sustained, these tariffs could significantly impact sectors such as housing, autos, and agriculture. Despite the disruption caused by these policies, Clark remains optimistic about the opportunities created by elevated market volatility. He argued that such environments allow active investors to distinguish high-quality companies from weaker ones, which he believes is an effective strategy for identifying long-term value amidst short-term uncertainty.
Clark noted that tariffs will accelerate de-globalization, bring back business to the United States, and improve supply chain management in domestic manufacturing. These factors are anticipated to benefit the potential leadership of US small-cap stocks in the market. Clark cited that small caps have favorable valuations and their earnings are expected to grow. Additionally, the cyclical nature of markets and heightened volatility have historically benefited small-cap stocks relative to large-cap equities. His research shows that following periods of elevated volatility measured by the VIX index, small-cap stocks like those in the Russell 2000 tend to outperform large-cap counterparts over three-year horizons. Clark also stressed the importance of contrarian thinking during uncertain times. Drawing from decades of experience as a small-cap investor, he underscored how understanding market inflection points and challenging conventional wisdom are crucial for achieving long-term outperformance.
Our Methodology
To gather the 10 best small-cap stocks to buy before they explode we used the Finviz stock screener and CNN as our sources. Using the screener we aggregated a list of small-cap stocks (Market Cap of $500 million to $2 billion) with an upside potential of more than 50%. After sorting the list by market capitalization we cross-checked the analysts’ average upside potential of each stock from CNN. Lastly, we ranked these stocks in ascending order of the number of hedge fund holders, sourced from Insider Monkey’s Q4 2024 database. Please note that the data was recorded on March 25, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode?
A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule.
Travere Therapeutics, Inc. (NASDAQ:TVTX) is another biopharmaceutical company focused on developing and delivering life-changing therapies for people with rare kidney and metabolic diseases. Its lead product is FILSPARI, which is an FDA-approved, non-immunosuppressive medication for slowing kidney function decline in adults with primary IgA nephropathy. In addition, the company is also developing sparsentan for focal segmental glomerulosclerosis and Pegtibatinase for classical homocystinuria.
On March 19, Leerink Partners analyst Joseph Schwartz maintained a Buy rating on the stock. Schwartz highlighted the submission of a supplemental New Drug Application for Filspari, which can open a significant market opportunity in focal segmental glomerulosclerosis, which is a condition with no approved therapies. This market is estimated to be worth $1 billion, supported by positive Phase 3 DUPLEX and Phase 2 DUET study data.
In addition, Travere Therapeutics, Inc. (NASDAQ:TVTX) reported strong sales figures for Filspari in 2024, surpassing expectations due to robust demand. Net product sales of FILSPARI totaled $50 million in 4Q 2024, reflecting growing adoption. The company ranks as one of the best small cap stocks to buy before they explode.
Overall, TVTX ranks 2nd on our list of best small-cap stocks to buy before they explode. While we acknowledge the potential of TVTX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TVTX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
